Collaborative program with exclusive patent, know-how, process and technology license to make, have made, use, sell, offer, import and sublicense products based on certain compounds against specific targets, including Chk1 inhibitors having activity with a Ki, pKb or EC50 for enzymes and non-enzymatic receptor antagonists or agonists, including those candidate products that were refused or returned by the other party, and compounds that meet the activity threshold against biotherapeutic targets, for the fields of vascular biology-based disease, oncology and inflammatory disease, including inflammatory and malignant angiogenesis, ocular conditions, underlying malignant and pre-dysplastic, endometriosis, atherosclerosis, cardiac ischemia, congestive heart failure, renal disease, thrombosis, asthma, chronic obstructive pulmonary, pulmonary hypertension, and transplant rejection.